We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intanza(R) 15 [mu]g Intradermal seasonal influenza vaccine: in older adults (aged <GT> or =60 years)
- Authors
Duggan ST; Plosker GL
- Abstract
Intradermal seasonal influenza vaccine delivered by a microneedle injection system (Intanza®) contains inactivated split virion antigens from influenza type A (H1N1 and H3N2) and B strains as recommended annually by the WHO and the EU for the prevention of seasonal influenza.In randomized, comparator-controlled, phase III trials in elderly volunteers, Intanza® 15µg elicited a strong immune response against influenza virus. In a pivotal trial, seroprotection rates with Intanza® 15µg were significantly greater than with the intramuscular comparator vaccine Vaxigrip® (primary endpoint).A strong immune response was also observed with Intanza® 15µg following second and third annual vaccinations in consecutive seasons in terms of seroprotective antibody titres for all three strains (H1N1, H3N2 and B).In another phase III trial, Intanza® 15µg was as immunogenic as the intramuscular, adjuvanted vaccine Fluad®, with noninferiority established in terms of ratios of geometric mean titres against H1N1 and B strains using the haemagglutinin inhibition method and against all three strains using the single radial haemolysis method.Intanza® 15µg was generally well tolerated in clinical trials in the elderly, with the most common adverse events observed being solicited injection-site reactions. The majority of solicited injection-site reactions were mild and spontaneously resolved within 1-3 days of onset; transient, visible injection-site reactions with the intradermal route of injection are not surprising as the vaccine is injected close to the skin surface.
- Publication
Drugs & Aging, 2010, Vol 27, Issue 7, p597
- ISSN
1170-229X
- Publication type
Journal Article
- DOI
10.2165/11203880-000000000-00000